Brought to you by 
Pernix buys Zogenix's controversial pain drug Zohydro ER franchise
30 Jan 2023
Executive Summary
Pernix Therapeutics Holdings Inc. bought Zogenix Inc.’s Zohydro ER (hydrocodone bitartrate capsules) assets for $100mm--$30mm cash, $20mm in Pernix stock (1.68mm shares), and a $50mm six-month promissory note--plus up to $12.5mm in regulatory and $271mm in pre-determined annual sales milestone targets of up to $1bn annually.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pernix buys Zogenix's controversial pain drug Zohydro ER franchise
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice